Cory Renauer
Value, research analyst, biotech, small-cap

Sequenom Billing Code Drama An Opportunity For Long-Term Investors

San Diego's Sequenom, Inc. (NASDAQ:SQNM) is a not yet profitable biotech in the highly competitive molecular diagnostics space. The company provides genetic analysis solutions through two operating segments, Molecular Diagnostics, and Genetic Analysis. The Molecular Diagnostics segment performs testing services using its laboratory developed tests (LDTs). The Genetic Analysis segment involves products and services for research use only.

LDT name

MaterniT21 PLUS

SensiGene RHD

Heredi-T CF

RetnaGene AMD


Fetal aneuploidies, or trisomies

Fetal Rhesus D factor

Cystic fibrosis

Age-related macular degeneration

The Molecular diagnostics segment offers four separate tests, of which MaterniT21 PLUS is the most popular.

5% more tests run and 16% less revenue

Sequenom recognizes Diagnostic Service revenues, which accounted for about 70% of Q2...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details